Prakiraan wutah bathi resik saben saham kanggo taun ngarep Coherus BioSciences, Inc (CHRS)

Logo korporat perusahaan Coherus Biosciences (CHRS)

Growing physician confidence in new cancer therapy methods is driving the projected EPS growth chart for Coherus Biosciences (CHRS) for the coming year, where the 15.50 mark serves as the current benchmark. The business is transitioning from biosimilars to innovation, leveraging profits from analogs. Efficiency is increasing through a unified sales network that eliminates redundant marketing expenses.

Coherus BioSciences, Inc (CHRS): Prakiraan wutah bathi resik saben saham kanggo taun ngarep saka 04.07.2022 nganti 17.11.2026

Ringkesan rincian data analitis Coherus (CHRS)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:Coherus BioSciences, Inc
Produk dadi Coherus BioSciences Inc.

Coherus Biosciences (CHRS) is shifting from mass-market biosimilars toward the development of proprietary oncology drugs to combat pricing erosion. This indicator measures the percentage change in expected earnings per share (EPS) for the coming year, aggregating forecasts from leading analysts. The metric allows investors to assess the monetization potential of new antibodies relative to current costs. Use the company's projected EPS trend for the next year as a benchmark for timely portfolio adjustments.

Analisis pesaing Coherus Biosciences

INCY (incyte.com) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep hutch-med.com HCM|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Nuvation Corp (NUVB)|DAWN - Prakiraan wutah bathi resik saben saham ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Monopar Pharma MNPR|Inhibrx Corp - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|IMAB - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Fennec Pharmaceuticals|HRTX: Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep Nuvectis NVCT|Prakiraan wutah bathi saben saham kanggo taun ngarep CRBP|Prakiraan wutah bathi resik saben saham ing taun ngarep Cardiff Oncology CRDF|Prakiraan wutah bathi saben saham kanggo taun ngarep BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Dinamika bathi saben saham sing diarepake ing taun ngarep|Lixte Biotechnology - Prakiraan wutah bathi saben saham kanggo taun ngarep|Proyeksi tambahing bathi saben saham ing taun ngarep CTXR (Citius Pharma)|Cellectar - Prakiraan wutah bathi kanggo taun ngarep|Dinamika bathi saben saham sing diarepake ing taun ngarep BLRX (BioLineRx Corp)|CANF: Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Aprea (APRE)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep kaziatherapeutics.com|SLXN: Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi kanggo taun ngarep NCNA|Prakiraan wutah bathi kanggo taun ngarep Chimerix Inc (CMRX)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep|KRON: Prakiraan wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Kintara Therapeutics Inc|oncternal.com (ONCT) - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep PRTG (Portage Biotech Corp)